Faculty of Sport Sciences, Universidad Europea de Madrid, Madrid, Spain.
Research Institute of the Hospital 12 de Octubre (i+12), Madrid, Spain.
Scand J Med Sci Sports. 2020 Jan;30(1):126-134. doi: 10.1111/sms.13545. Epub 2019 Oct 6.
Childhood cancer patients are at risk of developing important adverse effects, mortality and disease relapse after treatments, which has a substantial economic impact on healthcare systems. The objective of this study was to determine the effects of supervised inhospital exercise on clinical endpoints during childhood cancer treatment. 169 children with a new diagnosis of cancer were divided into an exercise intervention (n = 68, 11 ± 4 years) or a control group (n = 101, 11 ± 3 years). The cohort was followed up from the start of treatment for up to five years. Supervised inhospital exercise intervention was performed during the neoadjuvant (for solid tumors) or intensive chemotherapy treatment period (for leukemias). The median duration of the intervention was 22 (interquartile range, 14-28) weeks. We assessed survival, risk of disease relapse or metastasis, and days of hospitalization (primary outcomes), and cardiovascular function, anthropometry and blood variables (secondary outcomes). No exercise-related adverse events were noted. The exercise group had significantly less days of hospitalization than the control group (P = .031), resulting in a lower (~-17%) mean total economic cost of hospitalization in the former. Moreover, echocardiography-determined left ventricular function (ejection fraction and fractional shortening) was significantly impaired in the control group after treatment compared with baseline, whereas it was maintained in the exercise group (P = .024 and .021 for the between-group differences, respectively). In conclusion, supervised inhospital exercise intervention is safe and plays a cardioprotective role, at least in the short term, in children with cancer, also reducing hospitalization time, and therefore alleviating the economic burden.
儿童癌症患者在治疗后有发生重要不良反应、死亡和疾病复发的风险,这对医疗保健系统造成了重大的经济影响。本研究的目的是确定监督住院内运动对儿童癌症治疗期间临床终点的影响。169 名新诊断为癌症的儿童被分为运动干预组(n=68,11±4 岁)或对照组(n=101,11±3 岁)。该队列从治疗开始随访长达五年。监督住院内运动干预在新辅助(实体瘤)或强化化疗治疗期间进行。干预的中位数持续时间为 22(四分位距,14-28)周。我们评估了生存、疾病复发或转移的风险以及住院天数(主要结局),以及心血管功能、人体测量学和血液变量(次要结局)。未观察到与运动相关的不良事件。运动组的住院天数明显少于对照组(P=0.031),导致前者的总住院经济成本平均降低了约 17%。此外,与基线相比,对照组在治疗后超声心动图确定的左心室功能(射血分数和缩短分数)明显受损,而运动组则得到维持(组间差异分别为 P=0.024 和 0.021)。总之,监督住院内运动干预是安全的,至少在短期内对癌症患儿具有心脏保护作用,还可以减少住院时间,从而减轻经济负担。